💊 ยา A-Z 🧬 เป้าหมาย 🛠 เครื่องมือ 📚 คู่มือ
ยาทั้งหมด หมวดหมู่ยา ด้านการรักษา ผลข้างเคียง
คู่มือ อภิธานศัพท์ ไทม์ไลน์
การเปรียบเทียบ เส้นทางของยา กลุ่มยา
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Antihemophilic Factor, Pegylated (Mw 20000) Human Sequence Recombinant

CHEMBL4594584 Phase 4 ได้รับการอนุมัติ Unknown
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
508.6 g/mol
LogP
-3.6
Phase
4

A recombinant form of clotting Factor VIII that has been chemically modified with polyethylene glycol to extend its time in circulation, reducing the frequency of injections needed. It is used to prevent and treat bleeding episodes in people with hemophilia A.

น้ำหนักโมเลกุล

508.6000 g/mol

LogP

-3.60

TPSA

197.00 Ų

Lipinski RO5

ไม่ผ่าน

กลไกการออกฤทธิ์

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
COCCNC(=O)OCC(COC(=O)NCCOC)OCCCC(=O)NCCCC[C@@H](C(=O)O)N

                

                

                
                

                    
InChI

                    
InChI=1S/C21H40N4O10/c1-31-12-9-24-20(29)34-14-16(15-35-21(30)25-10-13-32-2)33-11-5-7-18(26)23-8-4-3-6-17(22)19(27)28/h16-17H,3-15,22H2,1-2H3,(H,23,26)(H,24,29)(H,25,30)(H,27,28)/t17-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C21H40N4O10

                    

                    
                    

                        
HBD / HBA

                        
5 / 11

                    

                    
                    

                        
พันธะที่หมุนได้

                        
23

                    

                    
                    
                    

                        
อะตอมหนัก

                        
35

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
คำถามที่พบบ่อย

                

                    
                    

                        
                        

                            
A recombinant form of clotting Factor VIII that has been chemically modified with polyethylene glycol to extend its time in circulation, reducing the frequency of injections needed. It is used to prevent and treat bleeding episodes in people with hemophilia A.

                        

                    

                    

                    

                    
                    

                        
                        

                            
As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Antihemophilic Factor, Pegylated (Mw 20000) Human Sequence Recombinant is an approved drug. It has reached clinical phase 4. It is classified as a Unknown.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL4594584.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 86278357.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
ข้อจำกัดความรับผิดชอบทางการแพทย์

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.